Clinical investigation of the efficacy and safety of continuous intravenous Diltiazem for patients with refractory angina pectoris
- VernacularTitle:静脉滴注地尔硫治疗难治性心绞痛的临床观察
- Author:
Jianping LI
;
Wenhui DING
;
Junhua ZHANG
- Publication Type:Journal Article
- From:
Chinese Journal of Interventional Cardiology
2001;9(1):31-33
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of infusion Diltiazem for patients with refractory angina pectoris. Methods 10 patients with refractory angina pectoris received continuous intravenous Diltiazem 40～150 μg/min (2.4～9 mg/h) for 48 hours after cessation of intravenous nitroglycerin and oral β-blokers. Results With the single therapy of Diltiazem, 7 patients (70%) got satisfied results: 5 were free from and 2 were relieved of symptom; With the combination therapy of Diltiazem and intravenous nitroglycerin 60～120 μg/min after failed with Diltiazem alone, 3 (30%) patietns got satisfied results: 1 was free from and 2 were relieved of symptom. There is no severe side effects, including hypotension, bradycardia, cardiac function deterioration. Acute myocardial infarction, death and emergency interventional therapy did not occurred in all the 10 patients during the therapy period. Coronary angiography were performed in 8 patients within 1 week after the patients were stabled, 5 patients received PTCA and stent implantation and 3 patients received CABG. Conclusions Continuous intravenous Diltiazem 40～150 μg/min (2.4～9 mg/h) or combination with intravenous nitroglycerin 60～120 μg/min is an efficient and safe therapy for patients with refractory angina pectoris.
